Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
14-week randomized double-blind placebo-controlled trial of NP031112 (GSK3 inhibitor) in mild to moderate Alzheimer's disease
2008-005778-11Phase 2Terminated
- Sponsor
- Noscira S.A.
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tideglusib in Alzheimer's disease (AD) (4 arms), sponsored by Noscira S.A. Primary endpoint: Adverse events. Started Sep 2008; status: terminated.
02
Drugs
tideglusib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2008-005778-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005778-11.